Pressmeddelanden, rapporter och bolagsmeddelande för Curasight

The registration of new shares from the Rights Issue has been completed with the Danish Business Authority. A total of 23,737,362 shares were subscribed, including a guarantee subscription, increasing the company's share capital by DKK 1,186,868.10. Curasight's share capital now totals DKK 2,244,312.10, equivalent to 44,886,242 shares, with each share valued at DKK 0.05. The new shares are expected to begin trading on June 6, 2025, and convert to ordinary shares by June 10, 2025. Sedermera Corporate Finance AB is the global coordinator and bookrunner, DLA Piper is the legal advisor, and Danske Bank A/S is the settlement agent. For more information, contact Sedermera Corporate Finance AB or Ulrich Krasilnikoff, CEO of Curasight A/S.

At Curasight's Annual General Meeting, several resolutions were passed. The shareholders reviewed and approved the Board of Directors' report on the company's activities and the annual report for 2024. The decision was made to carry forward the profit for 2024 to the next year. The existing board members were re-elected, including Kirsten Aarup Drejer as chairman and Lars Trolle as vice-chairman. PricewaterhouseCoopers was re-elected as the auditor. A proposal to authorize the issuance of up to 7,100,000 warrants for directors, executives, and key employees was approved, with the authorization valid until May 28, 2030. Additionally, the chairman of the meeting, Ulrik Bangsbo Hansen, was authorized to register these resolutions. The updated articles of association and meeting minutes will be available on the company's website.

Curasight's CEO, Ulrich Krasilnikoff, expressed satisfaction with the company's ability to secure new capital amid challenging market conditions, enabling the continued development of cancer treatment options uTRACE® and uTREAT®. The company welcomed new strategic shareholders, Curium and Pentwater, and aims to focus on key clinical milestones, including the completion of a Phase II study on prostate cancer and the initiation of a Phase I study on aggressive brain cancer. The Rights Issue concluded with approximately 47% of shares subscribed, involving 23,737,362 shares, with guarantors covering the shortfall. The company's share capital increased, leading to a 52.9% dilution. Krasilnikoff and Andreas Kjær saw changes in their ownership percentages, while Curium and Pentwater became significant shareholders. No interim share trading will occur, and Sedermera Corporate Finance AB, DLA Piper, and Danske Bank A/S are involved as advisors. The announcement includes legal disclaimers and notes potential risks in forward-looking statements.

Översikten presenterar transaktioner kopplade till deltagande i "Right Issue 2025" för bolaget Curasight. Fem personer från företagets ledning och styrelse deltog, inklusive styrelseordföranden Kirsten Drejer, vice ordföranden Lars Trolle, VD och CFO Ulrich Krasilnikoff, CMO och CSO Andreas Kjær, samt medgrundaren Jacob Madsen. Sammanlagt köptes 2,712,328 nya aktier till ett totalt värde av 5,370,409.44 DKK. För mer information om Curasight kan Ulrich Krasilnikoff kontaktas via telefon eller e-post.

The agenda for Curasight's Annual General Meeting includes several key items. The Board of Directors will report on the company's activities over the past financial year and seek approval for the annual report. They propose that the 2024 financial results be carried forward to the next year. The meeting will also involve the election of board members, with proposals for re-election of current members, and the re-election of PricewaterhouseCoopers as the company's auditor. There are proposals for new resolutions, including the introduction of an incentive program involving the issuance of up to 7,100,000 warrants to key personnel, which aims to align their interests with those of the shareholders. This program is designed to retain and attract talent and is seen as strategically important for the company's growth. The warrants will be issued at market value, and the program may result in a 10% dilution of the company's share capital. The Board also seeks authorisation for the chairman to register the resolutions and make necessary amendments as required by authorities. Most agenda items require a simple majority vote, while the incentive program requires a two-thirds majority. Shareholders have rights to attend, vote, and submit questions at the meeting. Information and documents related to the meeting are available on the company's website. The meeting will be conducted in Danish.

Ingen prospekt har upprättats för den aktuella företrädesemissionen. Företaget har istället tagit fram ett informationsdokument enligt artikel 1.4 db) i EU-förordningen 2024/2809, som finns tillgängligt på företagets webbplats. Dokumentet ger mer information om företrädesemissionen och företaget och följer bilaga IX i prospektförordningen (EU) 2017/1129. Viktiga datum inkluderar handel med teckningsrätter från 30 april till 14 maj 2025, teckningsperiod från 2 maj till 16 maj 2025, och det förväntade publiceringsdatumet för resultatet den 21 maj 2025. Sedermera Corporate Finance AB är global koordinator och bokförare, DLA Piper är juridisk rådgivare, och Danske Bank A/S är avvecklingsagent. Kontakter för mer information är tillgängliga för både företrädesemissionen och företaget.

The Phase 1 trial is a significant step for Curasight in advancing its theranostic platform and establishing itself as a therapeutic company. Curasight is collaborating with Premier Research, a Clinical Research Organization experienced in international diagnostic and therapeutic trials with radiopharmaceutical agents, to ensure the trial's efficient execution. The trial aims to investigate Curasight’s uTREAT ligand as a treatment for Glioblastoma patients scheduled for brain surgery. The trial design is based on previous research and discussions with experts. Curasight's uTREAT platform is part of its uPAR theranostic solution, which includes uTRACE for diagnostics and uTREAT for targeted treatment in brain cancer. Premier Research specializes in clinical trial management, particularly in oncology and neuroscience. For more information, contact Curasight's CEO, Ulrich Krasilnikoff.

Curasight is conducting a rights issue where existing shareholders registered by May 1, 2025, receive 43 subscription rights per share. Eighteen rights allow the purchase of one new share at DKK 1.98 each. Full subscription could raise approximately DKK 100 million before costs. The issue is backed by commitments totaling about DKK 47 million, covering 47% of the issue. The subscription period runs from May 2 to May 16, 2025, with trading of rights from April 30 to May 14, 2025. No prospectus is prepared; instead, an information document is available. The rights issue is primarily for investors in Denmark and Sweden, with restrictions in other regions. Sedermera Corporate Finance is coordinating, with DLA Piper as legal advisor and Danske Bank as the settlement agent. The announcement also includes legal disclaimers and notes on forward-looking statements.

Presentationerna kommer att omfatta en genomgång av nyemissionen av aktier och en uppdatering om företagets framsteg under första kvartalet 2025. Dessutom kommer ledningen att informera investerare om de senaste utvecklingarna under första kvartalet och förväntade nyheter om pipeline. HC Andersen Capitals presentation kommer att sändas live mellan 13:00 och 13:30 (CET) fredagen den 2 maj 2024 med fokus på den pågående nyemissionen. En arkiverad version av presentationen kommer att finnas tillgänglig på HC Andersen Capitals och Curasights webbplatser efter att presentationen är avslutad. För mer information om Curasight kan man kontakta Ulrich Krasilnikoff, VD, via telefon eller e-post.

Curasight has prepared a disclosure document for a Rights Issue in compliance with the EU Prospectus Regulation. This document is registered with the Danish Financial Supervisory Authority and is available on Curasight's website. Shareholders can subscribe to new shares through their financial institutions using a subscription form provided on the website. Key dates include the trading of subscription rights from April 30 to May 14, 2025, and the subscription period from May 2 to May 16, 2025. The outcome will be published on May 21, 2025. Each existing share will entitle the holder to 43 subscription rights, and 18 rights are needed to subscribe for one new share. Sedermera Corporate Finance AB is coordinating the issue, with DLA Piper as legal advisor and Danske Bank as the settlement agent. Contact details for further information are provided for both Sedermera Corporate Finance and Curasight's CEO, Ulrich Krasilnikoff.